FDA approves Roche’s Rozlytrek (entrectinib) for ROS1-positive, metastatic NTRK tumors
Roche announced the FDA has approved Rozlytrek™ (entrectinib) for treatment of adults with ROS1-positive, metastatic NSCLC. The FDA also granted accelerated approval to Rozlytrek for treatment of adult and paediatric patients 12 years of age and older with solid tumours that have a NTRK gene fusion. August 16, 2019